TY  - GEN
AU  - Correale,Pierpaolo
AU  - Remondo,Cinzia
AU  - Carbone,Salvatore Francesco
AU  - Ricci,Veronica
AU  - Migali,Cristina
AU  - Martellucci,Ignazio
AU  - Licchetta,Antonella
AU  - Addeo,Raffaele
AU  - Volterrani,Luca
AU  - Gotti,Giuseppe
AU  - Rotundo,Maria Saveria
AU  - Tassone,Pierfrancesco
AU  - Sperlongano,Pasquale
AU  - Abbruzzese,Alberto
AU  - Caraglia,Michele
AU  - Tagliaferri,Pierosandro
AU  - Francini,Guido
TI  - Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients
SN  - 1555-8576
PY  - 2010///1207
KW  - Adenocarcinoma
KW  - blood
KW  - Administration, Oral
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Angiopoietin-1
KW  - Antibodies, Monoclonal
KW  - administration & dosage
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Bevacizumab
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Carcinoma, Squamous Cell
KW  - Cisplatin
KW  - Drug Synergism
KW  - Enzyme-Linked Immunosorbent Assay
KW  - Etoposide
KW  - Female
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Middle Aged
KW  - Prospective Studies
KW  - Survival Rate
KW  - Thrombospondins
KW  - Treatment Outcome
KW  - Vascular Endothelial Growth Factor A
N1  - Publication Type: Clinical Trial, Phase I; Journal Article
UR  - https://doi.org/10.4161/cbt.9.9.11441
ER  -